Novabay Pharmaceuticals (NBY) 0.61 $NBY
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 28.32 (-0.74), MDT: 78.02 (+0.36), RARE: 62.06 (-0.83), PFE: 34.25 (+0.10), SUPN: 11.35 (-0.11), NRX: 7.41 (-0.12), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), SVA: 5.02 (+0.03), BLRX: 2.06 (+0.03), AMPH: 14.74 (+0.30), CHRS: 26.46 (-2.27), JNJ: 102.40 (+0.71), GNVC: 3.16 (+0.07), CYCC: 0.98 (+0.02), AZN: 72.70 (+1.80), DPRX: 14.00 (+0.49), TEVA: 62.10 (+0.55), NBY: 0.61 (-0.02)
The National Necrotizing Fasciitis Foundation Names NovaBay's NeutroPhase as its Official "Flesh Eating Disease" Wound Cleanser
PR Newswire - Tue Mar 17, 6:00AM CDT
The National Necrotizing Fasciitis Foundation (NNFF) today announced the NNFF has named NeutroPhase®, a wound cleanser made by NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), the official wound cleanser of the NNFF.
NBY: 0.61 (-0.02)
NovaBay Pharmaceuticals Provides Update on Avenova Sales Growth
Business Wire - Mon Mar 16, 6:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today provided an update on its commercial launch of Avenova(TM).
NBY: 0.61 (-0.02)
NovaBay Pharmaceuticals Signs Avenova and NeutroPhase Distribution Agreements
Business Wire - Mon Mar 09, 6:00AM CDT
--Agreements expand distribution of NovaBay's breakthrough products to more markets around the world
NBY: 0.61 (-0.02)
InsiderInsights.com Daily Round Up 3/5/15: OAS, CRR, NBY, SIR
InsiderInsights - at Seeking Alpha - Fri Mar 06, 11:45AM CST
CST: 43.38 (-0.31), SIR: 25.57 (+0.73), CRR: 32.05 (+0.52), WETF: 22.23 (+1.22), SAM: 277.36 (+9.46), QTWO: 21.65 (+0.09), MOH: 64.89 (-0.24), HTWO: 9.70 (-0.11), VCRA: 9.97 (-0.08), WIW: 11.27 (+0.01), HAFC: 20.79 (+0.04), SGEN: 38.86 (-0.83), MOSY: 1.94 (+0.06), CUDA: 38.33 (-1.64), SQBG: 10.06 (+0.09), ASGN: 38.80 (+0.13), HBI: 34.18 (-0.16), FTNT: 35.31 (-0.16), OAS: 13.80 (-0.16), NBY: 0.61 (-0.02)
NovaBay raises $4.9M in a private placement
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 9:30AM CST
NBY: 0.61 (-0.02)
NovaBay to distribute prescription Avenova for blepharitis and dry eye to pharmacies across the US through Cardinal Health
M2 - Tue Jan 27, 3:07AM CST
Biopharmaceutical company NovaBay Pharmaceuticals (NYSE MKT:NBY) said on Monday that it has entered into a nationwide distribution agreement for Avenova with Cardinal Health (CAH), which delivers prescription drugs to retail pharmacies, hospitals, mail-order facilities, physician offices and surgery centres across the US.
NBY: 0.61 (-0.02)
NovaBay signs Avenova distribution agreement with Cardinal Health
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 6:12AM CST
MCK: 229.94 (+4.19), CAH: 91.25 (+1.33), NBY: 0.61 (-0.02)
NovaBay Signs Avenova Distribution Agreement with Cardinal Health
Business Wire - Mon Jan 26, 6:02AM CST
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that it has signed a nationwide distribution agreement with Cardinal Health (NYSE: CAH), which delivers prescription drugs and many other products to retail pharmacies, hospitals, mail-order facilities, physician offices, surgery centers and other facilities across the U.S.
MCK: 229.94 (+4.19), CAH: 91.25 (+1.33), NBY: 0.61 (-0.02)
NovaBay Will Expand Marketing for Avenova At Arab Health 2015
ACCESSWIRE - Fri Jan 23, 6:00AM CST
NovaBay Pharmaceuticals will expand marketing and seek partners for Avenova at the world's largest healthcare conference
NBY: 0.61 (-0.02)
NovaBay Management and Key Industry Opinion Leaders to Hold Investment Community Conference Call Today, January 21st, 2015, at 12:00 p.m. ET
Business Wire - Wed Jan 21, 6:00AM CST
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company developing and commercializing non-antibiotic anti-infective products, will host an investment community conference call. Management will discuss the Company's refined business focus on products for the eye care market announced January 7, 2015, and sales force expansion announced January 20, 2015.
NBY: 0.61 (-0.02)
NovaBay Expands Sales Force for Avenova
Business Wire - Tue Jan 20, 1:38PM CST
--NovaBay management and key industry opinion leaders to hold an investment community conference call tomorrow, January 21st, at 12:00 p.m. Eastern time
NBY: 0.61 (-0.02)
NovaBay revamps strategy to focus on Eye Care
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:36AM CST
NBY: 0.61 (-0.02)
NovaBay Announces New Business Strategy Focusing on Products for Eye Care
Business Wire - Wed Jan 07, 6:00AM CST
--Seeking strategic alternatives for wound care, urology and dermatology assets
NBY: 0.61 (-0.02)
NovaBay Rebrands Its i-Lid Cleanser as Avenova
Business Wire - Mon Jan 05, 6:01AM CST
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of topical non-antibiotic anti-infective products, announces the rebranding of its i-Lid Cleanser with Neutrox(TM) as Avenova(TM) with Neutrox. This name change, effective immediately, helps NovaBay to differentiate prescription Avenova from other products marketed as eye cleaners, in particular over-the-counter (OTC) products not intended for continuous daily use.
NBY: 0.61 (-0.02)
Insider Trading Alert - NBY, WPX And KTOS Traded By Insiders
at The Street - Wed Dec 17, 10:42AM CST
Stocks with insider trader activity include NBY, WPX and KTOS
WPX: 11.09 (+0.16), KTOS: 5.82 (+0.10), NBY: 0.61 (-0.02)
Insider Trading Alert - EVTC, CRM And NBY Traded By Insiders
at The Street - Tue Dec 16, 10:38AM CST
Stocks with insider trader activity include EVTC, CRM and NBY
EVTC: 22.61 (+0.01), NBY: 0.61 (-0.02), CRM: 67.69 (-1.19)
NovaBay Executive Officers Report Insider Buying of 143,000 Common Shares to the SEC
ACCESSWIRE - Tue Dec 16, 6:00AM CST
EMERYVILLE, CA / ACCESSWIRE / December 16, 2014 / NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) reported that between December 2 and 12, 2014, NovaBay's CEO, CFO and Senior Vice President have filed Form 4's with the Security and Exchange Commission reporting their combined purchases of 143,000 shares of NovaBay common stock in open market purchases. During one the company's infrequent and brief open trading windows for insiders, NovaBay's CEO, Dr. Ron Najafi, purchased over 113,000 shares, the Company's CFO, Tom Paulson, purchased 20,000 shares and NovaBay's Senior Vice President of Ophthalmology, Dr. David Stroman, purchased 10,000 shares. Shares were purchased at prices ranging between $0.60 and $0.71; prices the Officers believe are a substantial discount to NovaBay's potential long term value.
NBY: 0.61 (-0.02)
Insider Trading Alert - CGIX, NBY And BIOA Traded By Insiders
at The Street - Fri Dec 12, 10:15AM CST
Stocks with insider trader activity include CGIX, NBY and BIOA
BIOA: 9.00 (+0.03), NBY: 0.61 (-0.02), CGIX: 7.85 (-0.11)
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 28.32 (-0.74), MDT: 78.02 (+0.36), RARE: 62.06 (-0.83), PFE: 34.25 (+0.10), SUPN: 11.35 (-0.11), NRX: 7.41 (-0.12), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), SVA: 5.02 (+0.03), BLRX: 2.06 (+0.03), AMPH: 14.74 (+0.30), CHRS: 26.46 (-2.27), JNJ: 102.40 (+0.71), GNVC: 3.16 (+0.07), CYCC: 0.98 (+0.02), AZN: 72.70 (+1.80), DPRX: 14.00 (+0.49), TEVA: 62.10 (+0.55), NBY: 0.61 (-0.02)
The National Necrotizing Fasciitis Foundation Names NovaBay's NeutroPhase as its Official "Flesh Eating Disease" Wound Cleanser
PR Newswire - Tue Mar 17, 6:00AM CDT
The National Necrotizing Fasciitis Foundation (NNFF) today announced the NNFF has named NeutroPhase®, a wound cleanser made by NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), the official wound cleanser of the NNFF.
NBY: 0.61 (-0.02)
NovaBay Pharmaceuticals Provides Update on Avenova Sales Growth
Business Wire - Mon Mar 16, 6:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today provided an update on its commercial launch of Avenova(TM).
NBY: 0.61 (-0.02)
NovaBay Pharmaceuticals Signs Avenova and NeutroPhase Distribution Agreements
Business Wire - Mon Mar 09, 6:00AM CDT
--Agreements expand distribution of NovaBay's breakthrough products to more markets around the world
NBY: 0.61 (-0.02)
InsiderInsights.com Daily Round Up 3/5/15: OAS, CRR, NBY, SIR
InsiderInsights - at Seeking Alpha - Fri Mar 06, 11:45AM CST
CST: 43.38 (-0.31), SIR: 25.57 (+0.73), CRR: 32.05 (+0.52), WETF: 22.23 (+1.22), SAM: 277.36 (+9.46), QTWO: 21.65 (+0.09), MOH: 64.89 (-0.24), HTWO: 9.70 (-0.11), VCRA: 9.97 (-0.08), WIW: 11.27 (+0.01), HAFC: 20.79 (+0.04), SGEN: 38.86 (-0.83), MOSY: 1.94 (+0.06), CUDA: 38.33 (-1.64), SQBG: 10.06 (+0.09), ASGN: 38.80 (+0.13), HBI: 34.18 (-0.16), FTNT: 35.31 (-0.16), OAS: 13.80 (-0.16), NBY: 0.61 (-0.02)
NovaBay raises $4.9M in a private placement
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 9:30AM CST
NBY: 0.61 (-0.02)
NovaBay to distribute prescription Avenova for blepharitis and dry eye to pharmacies across the US through Cardinal Health
M2 - Tue Jan 27, 3:07AM CST
Biopharmaceutical company NovaBay Pharmaceuticals (NYSE MKT:NBY) said on Monday that it has entered into a nationwide distribution agreement for Avenova with Cardinal Health (CAH), which delivers prescription drugs to retail pharmacies, hospitals, mail-order facilities, physician offices and surgery centres across the US.
NBY: 0.61 (-0.02)
NovaBay signs Avenova distribution agreement with Cardinal Health
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 6:12AM CST
MCK: 229.94 (+4.19), CAH: 91.25 (+1.33), NBY: 0.61 (-0.02)
NovaBay Signs Avenova Distribution Agreement with Cardinal Health
Business Wire - Mon Jan 26, 6:02AM CST
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that it has signed a nationwide distribution agreement with Cardinal Health (NYSE: CAH), which delivers prescription drugs and many other products to retail pharmacies, hospitals, mail-order facilities, physician offices, surgery centers and other facilities across the U.S.
MCK: 229.94 (+4.19), CAH: 91.25 (+1.33), NBY: 0.61 (-0.02)
NovaBay Will Expand Marketing for Avenova At Arab Health 2015
ACCESSWIRE - Fri Jan 23, 6:00AM CST
NovaBay Pharmaceuticals will expand marketing and seek partners for Avenova at the world's largest healthcare conference
NBY: 0.61 (-0.02)
NovaBay Management and Key Industry Opinion Leaders to Hold Investment Community Conference Call Today, January 21st, 2015, at 12:00 p.m. ET
Business Wire - Wed Jan 21, 6:00AM CST
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company developing and commercializing non-antibiotic anti-infective products, will host an investment community conference call. Management will discuss the Company's refined business focus on products for the eye care market announced January 7, 2015, and sales force expansion announced January 20, 2015.
NBY: 0.61 (-0.02)
NovaBay Expands Sales Force for Avenova
Business Wire - Tue Jan 20, 1:38PM CST
--NovaBay management and key industry opinion leaders to hold an investment community conference call tomorrow, January 21st, at 12:00 p.m. Eastern time
NBY: 0.61 (-0.02)
NovaBay revamps strategy to focus on Eye Care
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:36AM CST
NBY: 0.61 (-0.02)
NovaBay Announces New Business Strategy Focusing on Products for Eye Care
Business Wire - Wed Jan 07, 6:00AM CST
--Seeking strategic alternatives for wound care, urology and dermatology assets
NBY: 0.61 (-0.02)
NovaBay Rebrands Its i-Lid Cleanser as Avenova
Business Wire - Mon Jan 05, 6:01AM CST
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of topical non-antibiotic anti-infective products, announces the rebranding of its i-Lid Cleanser with Neutrox(TM) as Avenova(TM) with Neutrox. This name change, effective immediately, helps NovaBay to differentiate prescription Avenova from other products marketed as eye cleaners, in particular over-the-counter (OTC) products not intended for continuous daily use.
NBY: 0.61 (-0.02)
Insider Trading Alert - NBY, WPX And KTOS Traded By Insiders
at The Street - Wed Dec 17, 10:42AM CST
Stocks with insider trader activity include NBY, WPX and KTOS
WPX: 11.09 (+0.16), KTOS: 5.82 (+0.10), NBY: 0.61 (-0.02)
Insider Trading Alert - EVTC, CRM And NBY Traded By Insiders
at The Street - Tue Dec 16, 10:38AM CST
Stocks with insider trader activity include EVTC, CRM and NBY
EVTC: 22.61 (+0.01), NBY: 0.61 (-0.02), CRM: 67.69 (-1.19)
NovaBay Executive Officers Report Insider Buying of 143,000 Common Shares to the SEC
ACCESSWIRE - Tue Dec 16, 6:00AM CST
EMERYVILLE, CA / ACCESSWIRE / December 16, 2014 / NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) reported that between December 2 and 12, 2014, NovaBay's CEO, CFO and Senior Vice President have filed Form 4's with the Security and Exchange Commission reporting their combined purchases of 143,000 shares of NovaBay common stock in open market purchases. During one the company's infrequent and brief open trading windows for insiders, NovaBay's CEO, Dr. Ron Najafi, purchased over 113,000 shares, the Company's CFO, Tom Paulson, purchased 20,000 shares and NovaBay's Senior Vice President of Ophthalmology, Dr. David Stroman, purchased 10,000 shares. Shares were purchased at prices ranging between $0.60 and $0.71; prices the Officers believe are a substantial discount to NovaBay's potential long term value.
NBY: 0.61 (-0.02)
Insider Trading Alert - CGIX, NBY And BIOA Traded By Insiders
at The Street - Fri Dec 12, 10:15AM CST
Stocks with insider trader activity include CGIX, NBY and BIOA
BIOA: 9.00 (+0.03), NBY: 0.61 (-0.02), CGIX: 7.85 (-0.11)
